Acid inhibition in GERD - How much is enough?

American Journal of Gastroenterology

Volumn 99, Issue 6, 2004, Pages 997-999

  Achem, Sami R ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTON PUMP INHIBITOR;

DRUG EFFICACY; ESOPHAGITIS; ESOPHAGUS MUCOSA; ESOPHAGUS PH; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; HEALING; HUMAN; PATIENT SELECTION; PREVALENCE; PRIORITY JOURNAL; REVIEW; STOMACH MUCOSA; STOMACH PH;

ANTI-ULCER AGENTS; FEMALE; FOLLOW-UP STUDIES; GASTRIC ACID; GASTRIC ACIDITY DETERMINATION; GASTROESOPHAGEAL REFLUX; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; PROTON PUMPS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 3142708979     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2004.40316.x     Document Type: Review

References (29)

1. Nebel OT, Fornes MF, Castell DO. Symptomatic gastroesophageal reflux: Incidence and precipitating factors. Am J Dig Dis 1976;21:953-6.
2. Locke GR, Talley NJ, Fett SL, et al. Prevalence and clinical spectrum of gastro-esophageal reflux: A population based study in Olmsted County, Minnesota. Gastroenterology 1997;112:1148-56.
3. Harris G. Heartburn Drug Battle Likely. The New York Times August 20, 2003.
4. Martin RM, Lim AG, Kerry SM, et al. Trends in prescribing H2-receptor antagonists and proton pump inhibitors in primary care. Alim Pharmacol Ther 1998;12:797-803.
5. Bell NJV, Burget DL, Howden CW, et al. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 1992;5(suppl 1):59-67.
6. Fiorucci S, Santucci L, Chiucchiu S, et al. Gastric acidity and gastroesophageal reflux patterns in patients with esophagitis. Gastroenterology 1992;103:855-61.
7. Stein HJ, Hoeft S, DeMeester TR. Reflux and motility patterns in Barrett's esophagus. Dis Esophagus 1992;5:21-8.
8. Bremmer RM, Crookes PF, DeMeester TR, et al. Concentration of refluxed acid and esophageal mucosa injury. Am J Surg 1992;164:522-7.
9. Ouata-Lascar R, Fitzgerald RC, Triadafilopoulos G. Differentiation and proliferation in Barrett's esophagus the effects of acid suppression. Gastroenterology 1999;117:327-35.
10. Fitzgerald RC, Omary MB, Triadafilopoulos G. Dynamic effects of acid on Barett's esophagus. An ex-vivo proliferation and differentiation model. J Clin Invest 1996;2120-28.
11. Sampliner RE. Effect of up to 3 years of high-dose lansoprazole on Barrett's esophagus. Am J Gastroenterol 1994;89(10):1844-8.
12. Srinivasan R, Katz PO, Ramakrishnan DA, et al. Maximal acid reflux control for Barrett's esophagus: Feasible and effective. Alim Pharmacol Ther 2001;15:519-24.
13. Milkes D, Gerson LB, Triadafilopoulos G. Complete elimination of reflux symptoms does not guarantee normalization of intra-esophageal and intra-gastric pH in patients with gastro-esophageal reflux disease (GERD). Am J Gastroenterol doi: 10.1111/j.1572-0241.2004.30124.x.
14. Katz PO. Lessons learned from intra-gastric pH monitoring. J Clin Gastroenterol 2001;32(2):107-13.
15. Hungin APS, Rubin G, O'Flanagan H. Factors influencing compliance in long-term proton pump inhibitor therapy in general practice. Br J Gen Pract 1999;33:1016-9.
16. Marks RD, Richter JE, Rizzo J, et al. Omeprazole versus H2 receptor antagonists in treating patients with peptic strictures and esophagitis. Gastroenterology 1994;106:907-15.
17. Chiba N, De Gara CJ, Wilkonson JM, et al. Speed of healing and symptom relief in grade 11 to IV gastroesophageal reflux disease: A meta-analysis. Gastroenterology 1997;112:1798-810.
18. Kahrilas PJ, Falk GW, Johnson DA, et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux esophagitis patients: A randomized controlled trial. Alim Pharmacol and Ther 2000;14:1249-58.
19. Richter JE, Kahrilas PJ, Joahnson J, et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagtis: A randomized controlled study. Am J Gastroenterol 2001;96:656-65.
20. Castell DO, Kahrilas PJ, Richter JE, et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002;97:575-83.
21. Dodds WJ, Dent J, Hogan WJ, et al. Mechanisms of gastroesophageal relux in patients with reflux esophagitis. N Engl J Med 1982;307:1547-52.
22. Richter JE, Bradley LA, DeMeester TR, et al. Normal 24-hour ambulatory esophageal pH values. Influences of study center, pH electrode, age and gender. Dig Dis Sci 1992;37:849-56.
23. Kuo B, Castell DO. Optimal dosing of omeprazole 40 mg daily: Effects on gastric and esophageal pH and serum gastrin in healthy controls. Am J Gastroenterol 1996;91(8):1532-8.
24. Katzka DA, Castell DO. Successful elimination of reflux symptoms does not insure adequate control of acid reflux in patients with Barrett's esophagus. Am J Gastroenterol 1995;90:672-3.
25. Sharma P, Sampliner RE, Camargo E. Normalization of esophageal pH with high dose proton pump inhibitor therapy does not result in regression of Barrett's esophagus. Am J Gastroenterol 1997;92:582-5.
26. Ouatu-Lascar R, Triadafilopoulos G. Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal acid reflux in patients with Barrett's esophagus. Am J Gastroenterol 1998;93(5):711-6.
27. Bytzer P. Goals of therapy and guidelines for treatment success in symptomatic gastroesophageal reflux disease patients. Am J Gastroenterol 2003;98(Suppl.):S31-9.
28. Revicki DA, Crawley JA, Zodet MW, et al. Complete resolution of heartburn symptoms and health-related quality of life in patients with gastro-oesophageal efflux disease. Alim Pharmacol Ther 1999;13:1621-30.
29. Fass R, Sampliner RE, Malagon IB, et al. Failure of oesophageal acid control in candidates for Barrett's oesophagus reversal on a very high dose of proton pump inhibitor. Alim Pharmacol Ther 2000;14:597-602.